Taking the Myc out of Cancer: Toward Therapeutic Strategies to Directly Inhibit c-Myc

Sarah Madden, Aline Dantas de Araujo, Mara Gerhardt, David Fairlie, Jody Mason

Research output: Contribution to journalReview articlepeer-review

Abstract

c-Myc is a transcription factor that is constitutively and aberrantly expressed in over 70% of human cancers. Its direct inhibition has been shown to trigger rapid tumor regression in mice with only mild and fully reversible side effects, suggesting this to be a viable therapeutic strategy. Here we reassess the challenges of directly targeting c-Myc, evaluate lessons learned from current inhibitors, and explore how future strategies such as miniaturisation of Omomyc and targeting E-box binding could facilitate translation of c-Myc inhibitors into the clinic.
Original languageEnglish
Article number3
JournalMolecular Cancer
Volume20
DOIs
Publication statusPublished - 4 Jan 2021

Keywords

  • Oncogene
  • Transcription
  • leucine zipper
  • Peptide
  • protein-protein interaction

Cite this